Jane Street Group LLC Decreases Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Jane Street Group LLC lowered its stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 56.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 84,652 shares of the company’s stock after selling 108,141 shares during the quarter. Jane Street Group LLC’s holdings in Voyager Therapeutics were worth $495,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Victory Capital Management Inc. raised its position in shares of Voyager Therapeutics by 14.5% during the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after buying an additional 1,630 shares in the last quarter. Hunter Perkins Capital Management LLC raised its position in shares of Voyager Therapeutics by 3.3% during the 3rd quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock valued at $375,000 after buying an additional 2,025 shares in the last quarter. Empowered Funds LLC raised its position in shares of Voyager Therapeutics by 5.4% during the 3rd quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock valued at $262,000 after buying an additional 2,278 shares in the last quarter. Federated Hermes Inc. raised its position in shares of Voyager Therapeutics by 0.5% during the 2nd quarter. Federated Hermes Inc. now owns 554,214 shares of the company’s stock valued at $4,384,000 after buying an additional 2,638 shares in the last quarter. Finally, ClariVest Asset Management LLC raised its position in shares of Voyager Therapeutics by 2.7% during the 2nd quarter. ClariVest Asset Management LLC now owns 102,822 shares of the company’s stock valued at $813,000 after buying an additional 2,699 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Insider Transactions at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This represents a 5.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.53% of the company’s stock.

Analyst Upgrades and Downgrades

VYGR has been the topic of several recent research reports. Leerink Partners initiated coverage on shares of Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 target price on the stock. Canaccord Genuity Group restated a “buy” rating and set a $14.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Citigroup started coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They set a “buy” rating and a $12.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $17.43.

Voyager Therapeutics Price Performance

Shares of VYGR stock opened at $6.04 on Monday. The company has a market capitalization of $329.94 million, a P/E ratio of 8.51 and a beta of 0.93. The company’s 50-day simple moving average is $6.21 and its two-hundred day simple moving average is $6.89. Voyager Therapeutics, Inc. has a one year low of $5.19 and a one year high of $11.44.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. The business had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the prior year, the firm earned ($0.59) EPS. On average, research analysts expect that Voyager Therapeutics, Inc. will post -0.89 EPS for the current fiscal year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.